The University of Chicago Header Logo

Gini Fleming

InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Illinois, ChicagoMD06/1985Medicine
    Oberlin, OhioBA06/1981Chemistry

    Collapse Research 
    Collapse research activities and funding
    U10CA180821     (GEORGE, SUZANNE ;HAHN, OLWEN ;PIANTADOSI, STEVEN)Apr 17, 2014 - Feb 28, 2025
    Alliance for Clinical Trials in Oncology Operations Center
    Role: Co-Principal Investigator

    U10CA041287     (KINDLER, HEDY L)Sep 30, 1986 - Mar 31, 2015
    Cancer and Leukemia Group B
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, Nanda R, Jaskowiak NT, Fleming GF, Olopade OI, Pearson AT, Huo D, Howard FM. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2023 Dec 26. PMID: 38146744.
      Citations:    Fields:    
    2. Swisher EM, Rayes N, Bowen D, Peterson CB, Norquist BM, Coffin T, Gavin K, Polinsky D, Crase J, Bakkum-Gamez JN, Blank SV, Munsell MF, Nebgen D, Fleming GF, Olopade OI, Law S, Zhou A, Levine DA, D'Andrea A, Lu KH. Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. 2023 Nov 01; 9(11):1547-1555. PMID: 37707822; PMCID: PMC10502696.
      Citations: 1     Fields:    Translation:Humans
    3. Fleming GF. Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer. J Clin Oncol. 2023 10 10; 41(29):4603-4604. PMID: 37797408.
      Citations:    Fields:    Translation:Humans
    4. Duska LR, Zamarin D, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer. JCO Precis Oncol. 2023 Sep; 7:e2300235. PMID: 37797273.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Zhao F, Freeman JQ, Jaskowiak N, Fleming GF, Nanda R, Lauderdale DS, Olopade OI, Huo D. Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. Res Sq. 2023 Aug 10. PMID: 37609132; PMCID: PMC10441518.
    6. Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 10 20; 41(30):4779-4789. PMID: 37364223; PMCID: PMC10602497.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Chen N, Hahn O, Fleming G, Huo D, Nanda R. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83. PMID: 37120458; PMCID: PMC10224832.
      Citations: 2     Fields:    Translation:Humans
    8. Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Chen N, Hahn O, Fleming G, Huo D, Nanda R. The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer. Res Sq. 2023 Mar 16. PMID: 36993723; PMCID: PMC10055663.
    9. Zhao F, Miyashita M, Hattori M, Yoshimatsu T, Howard F, Kaneva K, Jones R, Bell JSK, Fleming GF, Jaskowiak N, Nanda R, Zheng Y, Huo D, Olopade OI. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329. PMID: 36995716; PMCID: PMC10064259.
      Citations: 8     Fields:    Translation:Humans
    10. Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA, SOFT and TEXT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCS. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382. PMID: 36521078; PMCID: PMC10419413.
      Citations: 12     Fields:    Translation:Humans
    11. Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT Investigators and the International Breast Cancer Study Group (a division of ETOP IBCSG Partner. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375. PMID: 36493334; PMCID: PMC10419521.
      Citations: 6     Fields:    Translation:Humans
    12. You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ, Mannel RS, Walker JL, Cappuccini F, Cohn D, Muzaffar M, Mutch D, Wahner-Hendrickson A, Martin L, Colomban O, Burger RA. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022 12 01; 40(34):3965-3974. PMID: 36252167; PMCID: PMC9746742.
      Citations: 7     Fields:    Translation:Humans
    13. Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322. PMID: 35900726; PMCID: PMC9335244.
      Citations: 9     Fields:    Translation:HumansCells
    14. Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224. PMID: 35583817.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    15. You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. J Clin Oncol. 2023 01 01; 41(1):107-116. PMID: 35867965; PMCID: PMC9788978.
      Citations: 2     Fields:    Translation:Humans
    16. Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, Tanner EJ, Fleming GF, Moroney JW, Pant A, Akasha AM, Davuluri RV, Kocherginsky M, Zhang B, Matei D. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022 07 15; 132(14). PMID: 35671108; PMCID: PMC9282926.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    17. Kurnit KC, Steiner M, Lastra RR, Weroha SJ, Cursio J, Lengyel E, Fleming GF, Conzen SD. High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas. Gynecol Oncol Rep. 2022 Jun; 41:100987. PMID: 35519002; PMCID: PMC9065886.
      Citations: 1     
    18. Pistilli B, Lohrisch C, Sheade J, Fleming GF. Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13. PMID: 35623026.
      Citations: 6     Fields:    Translation:Humans
    19. Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2022 06; 33(6):658. PMID: 35301096.
      Citations: 3     Fields:    Translation:Humans
    20. Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022 03; 10(3). PMID: 35288469; PMCID: PMC8921950.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    21. Asom AS, Lastra RR, Hasan Y, Weinberg L, Fleming GF, Kurnit KC. Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide? Gynecol Oncol Rep. 2022 Feb; 39:100925. PMID: 35059489; PMCID: PMC8760400.
      Citations: 1     
    22. Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35. PMID: 34224438; PMCID: PMC8664981.
      Citations: 1     Fields:    Translation:Humans
    23. Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287. PMID: 34930617; PMCID: PMC9399938.
      Citations: 3     Fields:    Translation:Humans
    24. Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253. PMID: 34906376.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    25. Wu M, Bennett JA, Reid P, Fleming GF, Kurnit KC. Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab. Gynecol Oncol Rep. 2021 Aug; 37:100837. PMID: 34368414; PMCID: PMC8326349.
      Citations: 3     
    26. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    27. Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL. Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381. PMID: 34112513.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    28. Shang L, Hattori M, Fleming G, Jaskowiak N, Hedeker D, Olopade OI, Huo D. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18. PMID: 33541403; PMCID: PMC7863526.
      Citations: 16     Fields:    Translation:Humans
    29. Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE, Fleming GF, Welch S, Dhani NC, Stockley T, Rath P, Karakasis K, Jones GN, Jenkins S, Rodriguez-Canales J, Tracy M, Tan Q, Bowering V, Udagani S, Wang L, Kunos CA, Chen E, Pugh TJ, Oza AM. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021 01 23; 397(10271):281-292. PMID: 33485453; PMCID: PMC10792546.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    30. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020; 12:1758835920974118. PMID: 33414846; PMCID: PMC7750903.
      Citations: 4     
    31. Zhao F, Copley B, Niu Q, Liu F, Johnson JA, Sutton T, Khramtsova G, Sveen E, Yoshimatsu TF, Zheng Y, Ibraheem A, Jaskowiak N, Nanda R, Fleming GF, Olopade OI, Huo D. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849. PMID: 33111220; PMCID: PMC7925344.
      Citations: 19     Fields:    Translation:Humans
    32. Paskett ED, Le-Rademacher J, Oliveri JM, Liu H, Seisler DK, Sloan JA, Armer JM, Naughton MJ, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C. A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance). Cancer. 2021 01 15; 127(2):291-299. PMID: 33079411; PMCID: PMC7790907.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    33. Naughton MJ, Liu H, Seisler DK, Le-Rademacher J, Armer JM, Oliveri JM, Sloan JA, Hock K, Schwartz M, Unzeitig G, Melnik M, Yee LD, Fleming GF, Taylor JR, Loprinzi C, Paskett ED. Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 01 15; 127(2):300-309. PMID: 33079393; PMCID: PMC7790999.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    34. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444. PMID: 33028595; PMCID: PMC8561652.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    35. Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850. PMID: 33078978; PMCID: PMC7676887.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    36. Kurnit KC, Reid P, Moroney JW, Fleming GF. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol. 2020 09; 158(3):531-537. PMID: 32641238.
      Citations: 3     Fields:    Translation:Humans
    37. Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645. PMID: 32513564; PMCID: PMC8227801.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    38. O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC). Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. PMID: 32378051.
      Citations: 6     Fields:    Translation:Humans
    39. Ribi K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, Salim M, van der Westhuizen A, Abdi E, Francis PA, Chia S, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Di Leo A, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359. PMID: 32274665.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    40. Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 07 01; 107(3):487-498. PMID: 32151670; PMCID: PMC7705948.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    41. MacKay HJ, Freixinos VR, Fleming GF. Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-11. PMID: 32239967.
      Citations: 9     Fields:    Translation:Humans
    42. Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486. PMID: 31992589; PMCID: PMC7269808.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    43. Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D, Provencher DM. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016. PMID: 31831561; PMCID: PMC7056559.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    44. Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM, SOFT and TEXT Investigators and International Breast Cancer Study Group, Láng I, Gómez HL. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303. PMID: 31618131; PMCID: PMC7164485.
      Citations: 41     Fields:    Translation:Humans
    45. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415. PMID: 31562800; PMCID: PMC6941439.
      Citations: 301     Fields:    Translation:HumansCTClinical Trials
    46. Yuen C, Fleming G, Meyers M, Soliven B, Rezania K. Myasthenia gravis induced by avelumab. Immunotherapy. 2019 10; 11(14):1181-1185. PMID: 31462152.
      Citations: 4     Fields:    Translation:HumansCells
    47. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377; PMCID: PMC9798913.
      Citations: 80     Fields:    Translation:HumansCellsCTClinical Trials
    48. Creutzberg CL, Lu KH, Fleming GF. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. J Clin Oncol. 2019 09 20; 37(27):2490-2500. PMID: 31403860.
      Citations: 6     Fields:    Translation:Humans
    49. Tonsing-Carter E, Hernandez KM, Kim CR, Harkless RV, Oh A, Bowie KR, West-Szymanski DC, Betancourt-Ponce MA, Green BD, Lastra RR, Fleming GF, Chandarlapaty S, Conzen SD. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019 07 24; 21(1):82. PMID: 31340854; PMCID: PMC6651939.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    50. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. PMID: 31216226; PMCID: PMC6879307.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    51. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 07; 69(4):258-279. PMID: 31074865.
      Citations: 231     Fields:    Translation:Humans
    52. Walker JL, Brady MF, Wenzel L, Fleming GF, Huang HQ, DiSilvestro PA, Fujiwara K, Alberts DS, Zheng W, Tewari KS, Cohn DE, Powell MA, Van Le L, Davidson SA, Gray HJ, Rose PG, Aghajanian C, Myers T, Alvarez Secord A, Rubin SC, Mannel RS. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390. PMID: 31002578; PMCID: PMC6544459.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    53. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648. PMID: 30948273.
      Citations: 187     Fields:    Translation:HumansCTClinical Trials
    54. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557. PMID: 30753272; PMCID: PMC6503628.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    55. Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. J Clin Oncol. 2019 04 10; 37(11):862-866. PMID: 30811287; PMCID: PMC6455715.
      Citations: 7     Fields:    Translation:Humans
    56. Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF. Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. Int J Gynecol Cancer. 2019 Feb; 29(2):357-364. PMID: 30683758.
      Citations: 9     Fields:    
    57. Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncol. 2018 07 12; 4(7):e173776. PMID: 29145543; PMCID: PMC6145732.
      Citations: 61     Fields:    Translation:Humans
    58. Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317. PMID: 29948021; PMCID: PMC6739841.
      Citations: 9     Fields:    Translation:HumansCells
    59. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Tondini C, Ciruelos E, Burstein HJ, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group, Láng I, Gómez HL, Bonnefoi HR. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. PMID: 29863451; PMCID: PMC6193457.
      Citations: 199     Fields:    Translation:Humans
    60. Ahmed A, Deng W, Tew W, Bender D, Mannel RS, Littell RD, DeNittis AS, Edelson M, Morgan M, Carlson J, Darus CJ, Fleury AC, Modesitt S, Olawaiye A, Evans A, Fleming GF. Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2018 08; 150(2):300-305. PMID: 29807694; PMCID: PMC6387790.
      Citations: 8     Fields:    Translation:Humans
    61. Collins JM, Fleming GF, Christ TN. Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim. J Oncol Pharm Pract. 2019 Jul; 25(5):1112-1118. PMID: 29768957.
      Citations: 3     Fields:    Translation:Humans
    62. Matsuda T, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y, Leisegang M. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367. PMID: 29720506.
      Citations: 39     Fields:    Translation:HumansCells
    63. West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Conzen SD, Györffy B. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446. PMID: 29636357; PMCID: PMC6530562.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    64. Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clin Cancer Res. 2018 05 15; 24(10):2285-2293. PMID: 29500276; PMCID: PMC5955794.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    65. Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, Mutch D, Temkin SM, Lynn J, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report. Gynecol Oncol. 2018 Feb 22. PMID: 29477660; PMCID: PMC9465931.
      Citations: 10     Fields:    
    66. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535; PMCID: PMC5978468.
      Citations: 253     Fields:    Translation:HumansCTClinical Trials
    67. Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 03; 148(3):507-514. PMID: 29352572.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    68. Tangen IL, Veneris JT, Halle MK, Werner HM, Trovik J, Akslen LA, Salvesen HB, Conzen SD, Fleming GF, Krakstad C. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecol Oncol. 2017 12; 147(3):672-677. PMID: 28927900.
      Citations: 9     Fields:    Translation:HumansCells
    69. Regan MM, Walley BA, Francis PA, Fleming GF, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O, Láng I, Gómez HL. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017 Sep 01; 28(9):2225-2232. PMID: 28911092; PMCID: PMC5834112.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    70. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249. PMID: 28807367; PMCID: PMC5697899.
      Citations: 34     Fields:    Translation:Humans
    71. SOFT, TEXT Investigators, International Breast Cancer Study Group, Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122. PMID: 28654365; PMCID: PMC5597253.
      Citations: 42     Fields:    Translation:Humans
    72. Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253. PMID: 28532857; PMCID: PMC5526627.
      Citations: 9     Fields:    Translation:Humans
    73. Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160. PMID: 28456378; PMCID: PMC5955699.
      Citations: 18     Fields:    Translation:Humans
    74. von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 03; 144(3):459-467. PMID: 28089376; PMCID: PMC5570471.
      Citations: 14     Fields:    Translation:Humans
    75. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Reply to L.B. Marks et al. J Clin Oncol. 2017 04 10; 35(11):1258-1259. PMID: 28068171.
      Citations:    Fields:    Translation:Humans
    76. Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911. PMID: 27601514; PMCID: PMC5063186.
      Citations: 8     Fields:    Translation:Humans
    77. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016 12 20; 34(36):4431-4442. PMID: 27646947.
      Citations: 55     Fields:    Translation:Humans
    78. Ribi K, Bernhard J, Luo W, Regan MM, Fleming GF, Francis PA. Reply to F. Tomao et al. J Clin Oncol. 2016 12; 34(34):4189-4190. PMID: 27621403; PMCID: PMC5477822.
      Citations:    Fields:    Translation:Humans
    79. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Ann Surg Oncol. 2017 Jan; 24(1):38-51. PMID: 27646018; PMCID: PMC5179596.
      Citations: 28     Fields:    Translation:Humans
    80. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e219-e234. PMID: 27659727.
      Citations: 58     Fields:    Translation:Humans
    81. Bestvina CM, Fleming GF. Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist. 2016 10; 21(10):1250-1259. PMID: 27412393; PMCID: PMC5061541.
      Citations: 52     Fields:    Translation:Humans
    82. Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD. A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus. 2016; 5(1):947. PMID: 27386391; PMCID: PMC4929099.
      Citations: 19     
    83. Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016 04 26; 114(9):956-64. PMID: 27092785; PMCID: PMC4984913.
      Citations: 16     Fields:    Translation:Humans
    84. Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol. 2016 07 01; 34(19):2221-31. PMID: 27044936; PMCID: PMC4962708.
      Citations: 61     Fields:    Translation:Humans
    85. Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8. PMID: 27016228; PMCID: PMC5119517.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    86. Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perelló A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10. PMID: 27022111; PMCID: PMC4872319.
      Citations: 39     Fields:    Translation:Humans
    87. Gibson SJ, Fleming GF, Temkin SM, Chase DM. The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. Front Oncol. 2016; 6:63. PMID: 27047797; PMCID: PMC4805611.
      Citations: 18     
    88. Ezewuiro O, Grushko TA, Kocherginsky M, Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF, Romero IL. Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy. PLoS One. 2016; 11(1):e0147145. PMID: 26788855; PMCID: PMC4720394.
      Citations: 21     Fields:    Translation:Humans
    89. Bellet M, Gray KP, Francis PA, Láng I, Ciruelos E, Lluch A, Climent MA, Catalán G, Avella A, Bohn U, González-Martin A, Ferrer R, Catalán R, Azaro A, Rajasekaran A, Morales J, Vázquez J, Fleming GF, Price KN, Regan MM. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 05 10; 34(14):1584-93. PMID: 26729437; PMCID: PMC4872316.
      Citations: 37     Fields:    Translation:Humans
    90. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol. 2016 Jan; 140(1):176-83. PMID: 26556766; PMCID: PMC4698212.
      Citations: 102     Fields:    Translation:HumansCells
    91. Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Villani L, Pizzolitto S, Sessa F, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G, SOFT and TEXT Investigators and International Breast Cancer Study Group, Szoke J, Doimi F, Öhlschlegel C, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat. 2015 Nov; 154(2):275-86. PMID: 26493064; PMCID: PMC4749471.
      Citations: 21     Fields:    Translation:Humans
    92. Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015 Oct; 139(1):17-22. PMID: 26216729; PMCID: PMC4600605.
      Citations: 29     Fields:    Translation:Humans
    93. VanderWeele DJ, Paner GP, Fleming GF, Szmulewitz RZ. Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. Front Oncol. 2015; 5:169. PMID: 26258074; PMCID: PMC4510409.
      Citations: 9     
    94. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. PMID: 26199386; PMCID: PMC4677671.
      Citations: 1     Fields:    Translation:Humans
    95. Fleming GF. Second-Line Therapy for Endometrial Cancer: The Need for Better Options. J Clin Oncol. 2015 Nov 01; 33(31):3535-40. PMID: 26195695.
      Citations: 24     Fields:    Translation:Humans
    96. Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62. PMID: 26115975; PMCID: PMC4556542.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    97. Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA, Bernhard J. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58. PMID: 26092816; PMCID: PMC4562429.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    98. He C, Chan C, Weichselbaum RR, Fleming GF, Yamada SD, Lin W. Nanomedicine for Combination Therapy of Cancer. EBioMedicine. 2015 May; 2(5):366-7. PMID: 26137577; PMCID: PMC4486458.
      Citations: 6     Fields:    Translation:HumansAnimals
    99. Francis PA, Regan MM, Fleming GF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 04 23; 372(17):1673. PMID: 25901437.
      Citations: 21     Fields:    Translation:Humans
    100. Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol. 2015 Jul; 138(1):55-61. PMID: 25895616.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    101. Jang M, Yew PY, Hasegawa K, Ikeda Y, Fujiwara K, Fleming GF, Nakamura Y, Park JH. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology. 2015 Nov; 4(11):e1030561. PMID: 26451311; PMCID: PMC4589054.
      Citations: 31     Fields:    
    102. Fleming GF. New drugs in ovarian cancer. Clin Adv Hematol Oncol. 2015 Apr; 13(4):223-5. PMID: 26352580.
      Citations:    Fields:    Translation:Humans
    103. Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecol Oncol. 2015 May; 137(2):216-22. PMID: 25769658.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    104. Fleming GF, Schumm P, Friberg G, Ratain MJ, Njiaju UO, Schilsky RL. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69. PMID: 25885822; PMCID: PMC4336691.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    105. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1574-82. PMID: 25589624; PMCID: PMC4383665.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    106. Francis PA, Regan MM, Fleming GF, Ciruelos E, Bellet M, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD, SOFT Investigators, International Breast Cancer Study Group, Láng I, Bonnefoi HR. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. PMID: 25495490; PMCID: PMC4341825.
      Citations: 221     Fields:    Translation:HumansCTClinical Trials
    107. Tew WP, Fleming GF. Treatment of ovarian cancer in the older woman. Gynecol Oncol. 2015 Jan; 136(1):136-42. PMID: 25448455.
      Citations: 13     Fields:    Translation:Humans
    108. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14. PMID: 25218906; PMCID: PMC4294183.
      Citations: 244     Fields:    Translation:HumansCTClinical Trials
    109. Maranville JC, Nanda R, Fleming GF, Skor MN, Di Rienzo A, Conzen SD. Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8. PMID: 25000515; PMCID: PMC4122588.
      Citations:    Fields:    Translation:Humans
    110. Liong S, Di Quinzio MK, Fleming G, Permezel M, Rice GE, Georgiou HM. New biomarkers for the prediction of spontaneous preterm labour in symptomatic pregnant women: a comparison with fetal fibronectin. BJOG. 2015 Feb; 122(3):370-9. PMID: 25056135.
      Citations: 22     Fields:    Translation:Humans
    111. Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85. PMID: 25016924; PMCID: PMC5166425.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    112. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators, International Breast Cancer Study Group, Láng I, Bonnefoi HR, Bernhard J. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18. PMID: 24881463; PMCID: PMC4175521.
      Citations: 228     Fields:    Translation:HumansCTClinical Trials
    113. Castonguay V, Lheureux S, Welch S, Mackay HJ, Hirte H, Fleming G, Morgan R, Wang L, Blattler C, Ivy PS, Oza AM. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014 Aug; 134(2):274-80. PMID: 24882554.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    114. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun; 4(3):137-144. PMID: 24766678; PMCID: PMC9258614.
      Citations: 46     Fields:    Translation:Humans
    115. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20; 32(12):1210-7. PMID: 24637999; PMCID: PMC3986384.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    116. Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35. PMID: 24637941; PMCID: PMC4165641.
      Citations: 6     Fields:    Translation:Humans
    117. Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014 Mar; 132(3):585-92. PMID: 24456823; PMCID: PMC4063288.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    118. Salgia S, Fleming GF, Lukas RV. Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci. 2014 Jul; 21(7):1250-1. PMID: 24412296.
      Citations: 3     Fields:    Translation:Humans
    119. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA, International Breast Cancer Study, GroupSOFT and TEXT Investigators. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100. PMID: 24095609; PMCID: PMC3855346.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    120. Bhatta SS, Hou N, Moton ZN, Polite BN, Fleming GF, Olopade OI, Huo D, Hong S. Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus. 2013; 2:356. PMID: 23961419; PMCID: PMC3736077.
      Citations: 12     
    121. Arowolo OA, Njiaju UO, Ogundiran TO, Abidoye O, Lawal OO, Obajimi M, Adetiloye AV, Im HK, Akinkuolie AA, Oluwasola A, Adelusola K, Kayode AA, Agbakwuru AE, Oduntan H, Babalola CP, Fleming G, Olopade OC, Falusi AG, Durosinmi MA, Olopade OI. Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J. 2013 Sep-Oct; 19(5):470-7. PMID: 23865786; PMCID: PMC4282544.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    122. Innocenti F, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A, Ramírez J. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81. PMID: 23670235; PMCID: PMC3858967.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    123. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. PMID: 23810467; PMCID: PMC3956307.
      Citations: 72     Fields:    Translation:HumansCTClinical Trials
    124. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9. PMID: 23776198; PMCID: PMC3699438.
      Citations: 14     Fields:    Translation:Humans
    125. Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):145-53. PMID: 23605083; PMCID: PMC4517667.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    126. Fleming GF. Management of recurrent EOC: the state of the art. Oncology (Williston Park). 2013 Apr; 27(4):298, 303-4. PMID: 23781693.
      Citations:    Fields:    Translation:Humans
    127. Stringer EM, Fleming GF. Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. Eur Endocrinol. 2013 Mar; 9(1):18-21. PMID: 30349605; PMCID: PMC6193520.
      Citations: 1     
    128. Stringer EM, Fleming GF. Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. Oncol Hematol Rev. 2013; 9(1):41-44. PMID: 25431800; PMCID: PMC4243922.
      Citations: 3     
    129. Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31. PMID: 22921155.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    130. Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93. PMID: 22872575; PMCID: PMC4410974.
      Citations: 31     Fields:    Translation:HumansAnimalsCTClinical Trials
    131. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63. PMID: 22245973; PMCID: PMC3658119.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    132. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83. PMID: 22204724.
      Citations: 864     Fields:    Translation:HumansCTClinical Trials
    133. Mackay HJ, Buckanovich RJ, Hirte H, Correa R, Hoskins P, Biagi J, Martin LP, Fleming GF, Morgan R, Wang L, Polintan R, Oza AM. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol. 2012 Apr; 125(1):136-40. PMID: 22138373; PMCID: PMC3303987.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    134. Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, Fleming GF, Ratain MJ. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63. PMID: 21447721; PMCID: PMC3077032.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    135. Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9. PMID: 21439817; PMCID: PMC4116678.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    136. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010 Jun; 117(3):473-6. PMID: 20347480.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    137. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, Wade JL, Agamah E, Vokes EE, Fleming GF. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40. PMID: 20117828; PMCID: PMC2842466.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    138. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010 Jan 15; 116(2):355-61. PMID: 19924790; PMCID: PMC2811766.
      Citations: 6     Fields:    Translation:Humans
    139. Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Mar; 116(3):301-6. PMID: 19945740.
      Citations: 30     Fields:    Translation:Humans
    140. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Jan; 116(1):15-20. PMID: 19840887; PMCID: PMC2804260.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    141. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19; 302(7):774-80. PMID: 19690310; PMCID: PMC3460383.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    142. Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6. PMID: 19476859; PMCID: PMC3683862.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    143. Miller DS, Fleming G, Randall ME. Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer. J Natl Compr Canc Netw. 2009 May; 7(5):535-41. PMID: 19460279.
      Citations:    Fields:    Translation:Humans
    144. Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204. PMID: 19383827; PMCID: PMC4707040.
      Citations: 39     Fields:    Translation:HumansCells
    145. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol. 2009 Apr; 36(2):145-54. PMID: 19332249.
      Citations: 22     Fields:    Translation:Humans
    146. Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009 Jan; 16(1):38-45. PMID: 19078928.
      Citations: 29     Fields:    Translation:Humans
    147. Mani A, Roda J, Young D, Caligiuri MA, Fleming GF, Kaufman P, Brufsky A, Ottman S, Carson WE, Shapiro CL. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009 Sep; 117(1):83-9. PMID: 19051009; PMCID: PMC2997435.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    148. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. PMID: 19010874; PMCID: PMC2586993.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    149. Paskett ED, Herndon JE, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA, Cancer and Leukemia Group B. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20. PMID: 18314912; PMCID: PMC3930158.
      Citations: 17     Fields:    Translation:Humans
    150. Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9. PMID: 18543100.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    151. Fleming G. Gemcitabine/docetaxel--welcome to a new standard. Gynecol Oncol. 2008 Jun; 109(3):313-5. PMID: 18534248.
      Citations: 1     Fields:    Translation:Humans
    152. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65. PMID: 18509177; PMCID: PMC4830463.
      Citations: 13     Fields:    Translation:Humans
    153. Gangadhar T, Cohen EE, Janisch L, House LK, Undevia SD, Fleming GF, Maitland ML, Ramirez J, Ratain MJ. A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):2545. PMID: 27947936.
    154. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost J, Wade Iii JL, Agamah E, Vokes EE, Fleming GF. Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol. 2008 May 20; 26(15_suppl):5585. PMID: 27950395.
    155. Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol. 2008 May 20; 26(15_suppl):5521. PMID: 27950843.
    156. Perez AT, Shaw HS, Fleming GF, Hershman DL, Franco S, Shapiro CL, Neal K, Cohen I, Tagliaferri M, Tripathy D. A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):1099. PMID: 27950963.
    157. Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF, Chicago Phase II Consortium, PMH Phase II Consortium, California Phase II Consortium. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55. PMID: 18423560; PMCID: PMC2699608.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    158. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group, Thürlimann B. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-1241. PMID: 18325918.
      Citations: 16     Fields:    Translation:Humans
    159. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E, Fackenthal DL, Chen P, Armstrong DK, Brahmer JR, Fleming GF, Vokes EE, Carducci MA, Ratain MJ. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27. PMID: 18309947; PMCID: PMC5846189.
      Citations: 88     Fields:    Translation:Humans
    160. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. PMID: 18165643.
      Citations: 193     Fields:    Translation:HumansCTClinical Trials
    161. Grushko TA, Filiaci VL, Mundt AJ, Olopade OI, Fleming GF, Gynecologic Oncology Group, Ridderstråle K. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan; 108(1):3-9. PMID: 17945336; PMCID: PMC2699629.
      Citations: 51     Fields:    Translation:HumansCells
    162. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007 Jul 10; 25(20):2983-90. PMID: 17617530.
      Citations: 37     Fields:    Translation:Humans
    163. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF, Rodgers WH, Gynecologic Oncology Group study. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul; 106(1):16-22. PMID: 17574073.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    164. Matthews AK, Sellergren SA, Huo D, List M, Fleming G. Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med. 2007 Jun; 13(5):555-62. PMID: 17604560.
      Citations: 40     Fields:    Translation:Humans
    165. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):387-93. PMID: 17362317.
      Citations: 90     Fields:    Translation:Humans
    166. Yong WP, Desai AA, Innocenti F, Ramirez J, Shepard D, Kobayashi K, House L, Fleming GF, Vogelzang NJ, Schilsky RL, Ratain MJ. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9. PMID: 17308893.
      Citations: 10     Fields:    Translation:Humans
    167. Modesitt SC, Tian C, Kryscio R, Thigpen JT, Randall ME, Gallion HH, Fleming GF, Gynecologic Oncology Group. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Apr; 105(1):59-65. PMID: 17150247.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    168. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR, Gynecologic Oncology Group study. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006 Nov 01; 107(9):2197-205. PMID: 17001661.
      Citations: 32     Fields:    Translation:Humans
    169. Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32. PMID: 16896006.
      Citations: 89     Fields:    Translation:HumansCellsCTClinical Trials
    170. Mould DR, Fleming GF, Darcy KM, Spriggs D. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol. 2006 Jul; 62(1):56-70. PMID: 16842379; PMCID: PMC1885077.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    171. Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H, Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8. PMID: 16773437.
      Citations: 11     Fields:    Translation:Humans
    172. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006 Jun; 4(6):459-68. PMID: 16981669.
      Citations: 28     Fields:    Translation:Humans
    173. Armstrong DK, Fleming GF, Markman M, Bailey HH. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Nov; 103(2):391-6. PMID: 16626792.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    174. Kao J, Conzen S, Fleming G, Recant W, Heimann R. In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276). Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):658. PMID: 16414377.
      Citations: 1     Fields:    Translation:Humans
    175. Fleming GF. Major progress for a less common cancer. J Clin Oncol. 2006 Jan 01; 24(1):6-8. PMID: 16330663.
      Citations: 1     Fields:    Translation:Humans
    176. Acharya S, Hensley ML, Montag AC, Fleming GF. Rare uterine cancers. Lancet Oncol. 2005 Dec; 6(12):961-71. PMID: 16321764.
      Citations: 34     Fields:    Translation:Humans
    177. Chen MD, Fleming GF, Mitchell S, Horowitz I. A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jan; 100(1):111-5. PMID: 16150481.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    178. Garcia AA, Oza AM, Hirte H, Fleming G, Tsao-Wei D, Roman L, Swenson S, Gandara D, Scudder S, Morgan R. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol. 2005 Jun; 23(16_suppl):5000. PMID: 27946267.
    179. Morgan RJ, Doroshow JH, Frankel P, Leong LA, Chow W, Fleming G, Garcia AA, Lenz HJ, Gandara D. A phase II trial of bryostatin in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium (CCC) trial. J Clin Oncol. 2005 Jun; 23(16_suppl):5140. PMID: 27946682.
    180. Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, Masters GA, Fleming GF, Heimann R. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1045-53. PMID: 15752883.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    181. Gupta S, Mauer AM, Ryan CW, Taber DA, Samuels BL, Fleming GF, University of Chicago Phase II Network. A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer. Am J Clin Oncol. 2005 Feb; 28(1):65-9. PMID: 15685037.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    182. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, Gallion H. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004 Aug; 15(8):1173-8. PMID: 15277255.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    183. Desai AA, Innocenti F, Janisch L, DeMario M, Shepard D, Ramirez J, Fleming GF, Ratain MJ. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84. PMID: 15235824.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    184. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 01; 22(11):2159-66. PMID: 15169803.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    185. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8. PMID: 15169793.
      Citations: 74     Fields:    Translation:HumansCTClinical Trials
    186. Mundt AJ, Rotmensch J, Waggoner SE, Yamada SD, Fleming GF. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2004 Mar; 92(3):801-5. PMID: 14984944.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    187. Poelman SM, Heimann R, Fleming GF, Recant WM, Conzen SD. Invariant p53 immunostaining in primary and recurrent breast cancer. Eur J Cancer. 2004 Jan; 40(1):28-32. PMID: 14687786.
      Citations: 1     Fields:    Translation:Humans
    188. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90. PMID: 14630685.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    189. Fleming GF. Adjuvant aromatase inhibitors: are we there yet? Cancer. 2003 Nov 01; 98(9):1779-81. PMID: 14584057.
      Citations:    Fields:    Translation:Humans
    190. Friberg G, Fleming G. Intraperitoneal chemotherapy for ovarian cancer. Curr Oncol Rep. 2003 Nov; 5(6):447-53. PMID: 14521802.
      Citations:    Fields:    Translation:Humans
    191. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, Ratain MJ. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7. PMID: 12853359.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    192. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, Bartlett N, Fleming G, Cohen HJ. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003 Jun 15; 21(12):2268-75. PMID: 12805325.
      Citations: 120     Fields:    Translation:Humans
    193. Sawyer MB, Ratain MJ, Bertucci D, Smith RP, Schilsky RL, Vogelzang NJ, Shulman K, Douglass EC, Fleming GF. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65. PMID: 12721264.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    194. Fleming GF. The best of times...the worst of times. Eur J Cancer. 2003 Apr; 39(6):715-7. PMID: 12651194.
      Citations:    Fields:    Translation:HumansAnimals
    195. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. PMID: 12637460.
      Citations: 321     Fields:    Translation:HumansCTClinical Trials
    196. Fleming GF, Meropol NJ, Rosner GL, Hollis DR, Carson WE, Caligiuri M, Mortimer J, Tkaczuk K, Parihar R, Schilsky RL, Ratain MJ. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27. PMID: 12473581.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    197. Kornblith AB, Kemeny M, Peterson BL, Wheeler J, Crawford J, Bartlett N, Fleming G, Graziano S, Muss H, Cohen HJ, Cancer and Leukemia Group B. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 2002 Sep 01; 95(5):989-96. PMID: 12209681.
      Citations: 51     Fields:    Translation:Humans
    198. Lathia C, Fleming GF, Meyer M, Ratain MJ, Whitfield L. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6. PMID: 12172976.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    199. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC, Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7. PMID: 11955746.
      Citations: 97     Fields:    Translation:Humans
    200. Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ, Shepard DR, Mani S, Kastrissios H, Learned-Coughlin S, Smith D, Ertel P, Magnum S, Janisch L, Fleming GF, Schilsky RL, Ratain MJ. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402. PMID: 11976834.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    201. Iyer L, Das S, Janisch L, Wen M, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ, Ramírez J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7. PMID: 11990381.
      Citations: 178     Fields:    Translation:Humans
    202. Benz CC, Hilakivi-Clarke L, Conzen S, Dorn RV, Fleming GF, Grant K, Greene G, Hellman S, Henderson C, Hoover R, Hryniuk W, Jeffrey S, Lippman M, Lung J, Mitchell M, Pike M. Expedition inspiration consensus 2001. Breast Cancer Res Treat. 2001 Dec; 70(3):213-9. PMID: 11804185.
      Citations:    Fields:    Translation:Humans
    203. Eng C, Mauer AM, Fleming GF, Bertucci D, Rotmensch J, Jacobs RH, Ratain MJ, Eng C, Mauer AM, Fleming GF, Bertucci D, Rotmensch J, Jacobs RH, Ratain MJ. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7. PMID: 11843253.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    204. Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, Rotmensch J, Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, Rotmensch J. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63. PMID: 11520140.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    205. Mundt AJ, Rotmensch J, Waggoner SE, Yamada D, Langhauser C, Fleming GF, Mundt AJ, Rotmensch J, Waggoner SE, Yamada D, Langhauser C, Fleming GF. Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies. Gynecol Oncol. 2001 Aug; 82(2):333-7. PMID: 11531289.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    206. Hartman AR, Fleming GF, Dillon JJ. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer. 2001 Jul; 2(2):138-43; discussion 144. PMID: 11899785.
      Citations: 1     Fields:    Translation:Humans
    207. Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20. PMID: 11350886.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    208. Laport GG, Fleming GF, Waggoner S, Zimmerman TM, Grinblatt DL, Williams SF. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant. 2001 Apr; 27(7):677-81. PMID: 11360105.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    209. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW, Whelan TJ, Pfister DG, American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 01; 19(5):1539-69. PMID: 11230499.
      Citations: 145     Fields:    Translation:Humans
    210. Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Feb 15; 19(4):1021-9. PMID: 11181665.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    211. Fleming GF, Waggoner SE, Rotmensch J, Langhauser C. Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel. Am J Clin Oncol. 2001 Feb; 24(1):52-7. PMID: 11232950.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    212. Fleming GF, Roth BJ, Baker SD, Sutton GP, Look KY, Muggia FM, Fracasso PM, McGuire WP, Fleming GF, Roth BJ, Baker SD, Sutton GP, Look KY, Muggia FM, Fracasso PM, McGuire WP. Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2000 Dec; 23(6):609-13. PMID: 11202808.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    213. Poelman SM, Adeyanju MO, Robertson MA, Recant WM, Karrison T, Fleming GF, Olopade OI, Conzen SD. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8. PMID: 11051254.
      Citations: 3     Fields:    Translation:Humans
    214. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000 Jul; 18(14):2710-7. PMID: 10894870.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    215. Ryan CW, Fleming GF, Janisch L, Ratain MJ. A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000 Jun; 23(3):297-300. PMID: 10857898.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    216. Goh BC, Fleming GF, Janisch L, Vogelzang NJ, Stadler WM, Ratain MJ. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94. PMID: 10854137.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    217. Fleming GF. Systemic therapy for advanced or recurrent endometrial carcinoma. Curr Oncol Rep. 1999 Sep; 1(1):47-53. PMID: 11122797.
      Citations: 1     Fields:    Translation:Humans
    218. Mundt AJ, Rotmensch J, Waggoner S, Quiet C, Fleming G. Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies. Gynecol Oncol. 1999 Jan; 72(1):45-50. PMID: 9889028.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    219. DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson S, Benner S, Lebwohl D. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol. 1999; 43(5):385-8. PMID: 10100593.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    220. Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. J Clin Oncol. 1998 Jun; 16(6):2032-7. PMID: 9626200.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    221. Mani S, Iyer L, Janisch L, Wang X, Fleming GF, Schilsky RL, Ratain MJ. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7. PMID: 9619763.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    222. Fleming GF, Waggoner SE, Rotmensch J, Skoog LA, Langhauser C. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol. 1997 Apr; 65(1):42-5. PMID: 9103389.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    223. Fleming GF, Waggoner SE, Wu S, Rotmensch J, Conley BA. Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a. J Natl Cancer Inst. 1997 Jan 15; 89(2):172-3. PMID: 8998189.
      Citations:    Fields:    Translation:Humans
    224. Fleming GF, O'Brien SM, Hoffman PC, Vokes EE, Vogelzang NJ, Schilsky RL, Waggoner SE, Ratain MJ. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32. PMID: 8996525.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    225. O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997 Jan; 15(1):177-86. PMID: 8996140.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    226. Sitas F, Bezwoda WR, Levin V, Ruff P, Kew MC, Hale MJ, Carrara H, Beral V, Fleming G, Odes R, Weaving A. Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer. 1997; 75(11):1704-7. PMID: 9184191; PMCID: PMC2223539.
      Citations: 17     Fields:    Translation:HumansCells
    227. Fleming GF, Janisch L, Vogelzang NJ, Vokes EE, Ratain MJ. Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. Cancer. 1996 Jun 01; 77(11):2308-12. PMID: 8635100.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    228. Mick R, Vokes EE, Lestingi TM, Gray-Stern W, Fleming GF, Schilsky RL, Ratain MJ. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59. PMID: 8653998.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    229. Fleming GF, Vokes EE, Buse JB, Mick R, Dushay J, Levitan D, Dolan ME. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. Cancer Chemother Pharmacol. 1996; 37(6):569-73. PMID: 8612311.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    230. Fleming GF, Ratain MJ, O'Brien SM, Schilsky RL, Hoffman PC, Richards JM, Vogelzang NJ, Kasunic DA, Earhart RH. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72. PMID: 8308929.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    231. Fleming GF, Heimann PS, Stephens JK, Simon MA, Ferguson MK, Benjamin RS, Samuels BL. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer. 1993 Aug 01; 72(3):714-8. PMID: 8334623.
      Citations: 25     Fields:    Translation:Humans
    232. Fleming GF, Schilsky RL. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19. PMID: 1462168.
      Citations: 9     Fields:    Translation:HumansAnimals
    233. Fleming GF, Amato JM, Agresti M, Safa AR. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol. 1992; 29(6):445-9. PMID: 1348973.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    234. Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol. 1991; 28(3):226-7. PMID: 1855280.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    235. Metson R, Fleming G, Oye RK. Nasopharyngeal mass: a manifestation of inflammatory otologic disease. Ann Otol Rhinol Laryngol. 1990 Jul; 99(7 Pt 1):543-6. PMID: 2369038.
      Citations:    Fields:    Translation:Humans
    Fleming's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (646)
    Co-Authors (77)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors